Home About us Contact
|
Home About us Contact | ||
|
|
||
Venous Sampling (venous + sampling)
Selected AbstractsLetter to the Editor: Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalaciaJOURNAL OF INTERNAL MEDICINE, Issue 4 2010N. Ito First page of article [source] Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shuntALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 3 2007G. T. EVERSON Summary Background, Measurement of portal inflow and portal-systemic shunt using cholate clearances could be useful in monitoring patients with liver disease. Aim, To examine relationships of cholate clearances and shunt to cirrhosis and varices and to define minimal sampling requirements. Methods, Five hundred forty-eight studies were performed in 282 patients enrolled in the Hepatitis C Antiviral Long-term Treatment to prevent Cirrhosis (HALT-C) trial. Stable, non-radioactive isotopes of cholate were administered intravenously and orally, clearances (Cliv and Cloral) were calculated from [dose/area under curve (AUC)] and cholate shunt from [(AUCoral:AUCiv) x (Doseiv:Doseoral) x 100%]. Results, Cholate Cloral and cholate shunt correlated with prevalences of both cirrhosis and varices (P < 0.0001 for all). Peripheral venous sampling at 5, 20, 45, 60 and 90 min defined the minimal model. Linear regression of cholate shunt determined from five points within 90 min vs. the standard method of 14 points over 3 h yielded slope of 1.0 and intercept 0.5% (r2 = 0.98, P < 0.0001). Results were identical in the 189 validation studies (slope 1.0, intercept 0.5%, r2 = 0.99, P < 0.0001). Conclusions, Cholate Cloral and cholate shunt may be useful in monitoring patients with liver disease. The 5-point model enhances application of cholate Cloral and cholate shunt in the non-invasive assessment of the portal circulation. [source] Effect of Hyperprolactinemia in Male Patients Consulting for Sexual DysfunctionTHE JOURNAL OF SEXUAL MEDICINE, Issue 5 2007Giovanni Corona MD ABSTRACT Introduction., The physiological role of prolactin (PRL) in male sexual function has not been completely clarified. Aim., The aim of this study is the assessment of clinical features and of conditions associated with hyperprolactinemia in male patients consulting for sexual dysfunction. Methods., A consecutive series of 2,146 (mean age 52.2 ± 12.8 years) male patients with sexual dysfunction was studied. Main Outcome Measures., Several hormonal and biochemical parameters were studied along with validated structured interviews (ANDROTEST and the Structured Interview on Erectile Dysfunction [SIEDY]). Mild hyperprolactinemia (MHPRL; PRL levels of 420,735 mU/L or 20,35 ng/mL) and severe hyperprolactinemia (SHPRL, PRL levels >735 mU/L, 35 ng/mL) were considered. Results., MHPRL and SHPRL were found in 69 (3.3%) and in 32 (1.5%) patients, respectively. Mean age and the prevalence of gynecomastia were similar in the two groups and in subjects with normal prolactin values. MHPRL was not confirmed in almost one-half of the patients after repetitive venous sampling. Hyperprolactinemia was associated with the current use of antidepressants, antipsychotic drugs, and benzamides. SHPRL was also associated with hypoactive sexual desire (HSD), elevated thyrotropin (TSH), and hypogonadism. The association between HSD and SHPRL was confirmed after adjustment for testosterone and TSH levels, and use of psychotropic drugs (hazard ratio [HR] = 8.60[3.85,19.23]; P < 0.0001). In a 6-month follow-up of patients with SHPRL, testosterone levels and sexual desire were significantly improved by the treatment. Conclusions., Our data indicate that SHPRL, but not MHPRL, is a relevant determinant of HSD. Gynecomastia does not help in recognizing hyperprolactinemic subjects, while the use of psychotropic medications and HSD are possible markers of disease. In the case of MHPRL, repetitive venous sampling is strongly encouraged. Corona G, Mannucci E, Fisher AD, Lotti F, Ricca V, Balercia G, Petrone L, Forti G, and Maggi M. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 2007;4:1485,1493. [source] Parathyroid hormone venous sampling prior to reoperation forprimary hyperparathyroidismANZ JOURNAL OF SURGERY, Issue 10 2003E. Estella Background: The surgical cure rate for primary hyperparathyroidismis greater than 95%. For those who have recurrent or persistentdisease, preoperative localization improves reoperation successrates. Selective parathyroid venous sampling (SPVS) for intact parathyroidhormone is particularly useful when non-invasive localization techniquesare negative or inconclusive. Methods: We present all known cases (n = 13)between 1994 and 2002 who had venous sampling for localization atour institution prior to reoperation for recurrent or persistentprimary hyperparathyroidism. Comparison was made with non-invasivelocalization procedures. Results of invasive and non-invasive localizationwere correlated with surgical findings. Results: Of the nine reoperated cases, eight had positive correlationsbetween SPVS and operative findings and histopathology. SPVS didnot reveal the parathyroid hormone source in one case with negativenon-invasive localization procedures. Comparisons between SPVS,computerized tomography (CT), and parathyroid scintigraphy (MIBI)as expressed in terms of true positive (TP), false positive (FP)and false negative (FN) were: SPVS , TP88.8%, FP 0%, FN 11.1%; CT , TP22.2%, FP 22.2%, FN 55.5%; and MIBI , TP33.3%, FP 0%, FN 66.6%. At least sevenof the nine operated cases have been cured; another remained normocalcaemic 2 weeksafter subtotal parathyroidectomy. Conclusion: In our institution SPVS has proven to be a valuabletool in cases with recurrent or persistent primary hyperparathyroidismand negative non-invasive localization procedures. [source] | ||||||||||